125 patents
Page 4 of 7
Utility
Regeneration of damaged tissue
10 Aug 21
A method of healing a wound including contacting a wound edge with a tropoelastin or elastin derived peptide in conditions for enabling a sustained contact of the tropoelastin with the wound edge for a time period for enabling re-epithelialization of the wound.
Anthony Steven Weiss
Filed: 24 Oct 18
Utility
Anti-SEZ6 antibody drug conjugates and methods of use
3 Aug 21
Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody drug conjugates to treat cancer.
David Liu, Julia Gavrilyuk, Alexander Schammel
Filed: 22 Jun 20
Utility
Medicine container, method of assembling the container, and method of dispensing the medicine from the container
6 Jul 21
A child-resistant medication container assembly that includes a blister card including a plurality of compartments each configured to support a dosage of medication, and a puck including a body portion, a recess that defines a partition wall in the body portion, and a plurality of openings defined in the partition wall.
Todd Marshall, Bhimaprasad Medhal, John G. Finch, Joy Elizabeth Borgardt
Filed: 22 Mar 18
Utility
Methods of treating heavy menstrual bleeding
29 Jun 21
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Kristof Chwalisz, Laura A. Williams, Rita I. Jain, Janine D. North, Juki Wing-Keung Ng
Filed: 15 Mar 19
Utility
Anti-huLRRC15 antibody drug conjugates and methods for their use
29 Jun 21
The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
Kurt C. Gish, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
Filed: 13 Dec 18
Utility
Light chain variable regions
15 Jun 21
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
Filed: 6 Dec 19
Utility
Modulators of ROR-gamma
18 May 21
David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Lanqi Jia, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Linghang Zhuang
Filed: 17 Nov 16
Utility
Dihydropyrrolopyridine inhibitors of ROR-gamma
11 May 21
David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Linghang Zhuang
Filed: 25 Apr 19
Utility
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
4 May 21
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Filed: 19 Dec 19
Utility
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
4 May 21
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Filed: 23 Mar 20
Utility
Crystalline forms of a Bruton's tyrosine kinase inhibitor
30 Mar 21
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof.
Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
Filed: 18 Nov 20
Utility
Protein tyrosine phosphatase inhibitors and methods of use thereof
23 Mar 21
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
Zhaoming Xiong, Jennifer M. Frost, Philip R. Kym, Xueqing Wang, Shuang Chen, Dennie Welch
Filed: 18 Sep 20
Utility
Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
23 Mar 21
Described herein are mutations that confer resistance to treatment with a BTK inhibitor.
Betty Chang, Joseph J. Buggy, Susanne M. Steggerda
Filed: 23 Jul 13
Utility
Anti-BMPR1B antibodies and methods of use
2 Mar 21
Provided are novel anti-BMPR1B antibodies and antibody drug conjugates, and methods of using such anti-BMPR1B antibodies and antibody drug conjugates to treat cancer.
Somdutta Roy, Laura Saunders, Casey Franklin, Kevin Martinez, Sarah Fong, Zhao Huang, Silvia Juarez, Alina He, Kathryn A. Loving, Sandro Vivona
Filed: 21 Apr 17
Utility
Methods and compositions for treating asthma using anti-IL-13 antibodies
16 Feb 21
The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof.
Catherine Tripp
Filed: 27 Jun 17
Utility
Modulators of the integrated stress pathway
9 Feb 21
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
Filed: 5 May 17
Utility
Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
26 Jan 21
Marina Gaillard, Philippe Letellier
Filed: 7 Nov 19
Utility
Methods of treating heavy menstrual bleeding
4 Jan 21
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Kristof Chwalisz, Laura A. Williams, Rita I. Jain, Janine D. North, Juki Wing-Keung Ng
Filed: 13 Mar 14
Utility
Anti-4-1BB antibodies and their uses
28 Dec 20
The present disclosure provides novel anti-4-1BB antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Yoshiko Akamatsu, Jieyi Wang
Filed: 25 May 17
Utility
Modulators of the integrated stress pathway
14 Dec 20
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
Filed: 4 May 17